OncBioMune goes with the mid-stage study of the therapeutic vaccine against prostate cancer; up 15% – OncBioMune Pharmaceuticals, Inc. (OTCMKTS: OBMP)

Nano cap OncBioMune Pharmaceuticals (OTCPK: OBMP + 14.8% ) is up below the average news volume that it has engaged a CRO to handle a Phase 2 clinical trial evaluating the lead ProscaVax candidate for first-line treatment of patients with localized prostate cancer, the first mid-stage study evaluating a prostate cancer vaccine in an active surveillance mode.

The study of 120 subjects is expected to begin this quarter.

ProscaVax specific antigen (PSA) and biological adjuvants interleukin-2 (IL-2) and granulocyte-macrophage colony stimulating factor (GM-CSF)